Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.

Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, Lopez-Berestein G, Landis MD, Rosato RR, Dave B, Wong S, Marchetti D, Sood AK, Chang JC.

Stem Cell Reports. 2018 Jan 9;10(1):212-227. doi: 10.1016/j.stemcr.2017.11.010. Epub 2017 Dec 14.

2.

Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.

Sahni JM, Gayle SS, Bonk KL, Vite LC, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA.

J Biol Chem. 2016 Nov 4;291(45):23756-23768. Epub 2016 Sep 20.

3.

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL.

Sci Transl Med. 2016 Apr 13;8(334):334ra53. doi: 10.1126/scitranslmed.aad3001. Erratum in: Sci Transl Med. 2019 Jan 23;11(476):.

4.

Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.

Tanei T, Choi DS, Rodriguez AA, Liang DH, Dobrolecki L, Ghosh M, Landis MD, Chang JC.

Breast Cancer Res. 2016 Jan 12;18(1):6. doi: 10.1186/s13058-015-0662-4.

5.

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.

Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS, Chang JC.

Breast Cancer Res. 2015 Feb 22;17:25. doi: 10.1186/s13058-015-0527-x.

6.

Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1.

Choi DS, Blanco E, Kim YS, Rodriguez AA, Zhao H, Huang TH, Chen CL, Jin G, Landis MD, Burey LA, Qian W, Granados SM, Dave B, Wong HH, Ferrari M, Wong ST, Chang JC.

Stem Cells. 2014 Sep;32(9):2309-23. doi: 10.1002/stem.1746.

7.

Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.

Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Adam A, Torres D, Zhang X, Dobrolecki LE, Wei W, Lewis MT, Dave B, Chang JC, Landis MD, Creighton CJ, Mancini MA, Tweardy DJ.

Oncogene. 2015 Mar 12;34(11):1341-53. doi: 10.1038/onc.2014.72. Epub 2014 Mar 31.

8.

Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.

Sahin O, Wang Q, Brady SW, Ellis K, Wang H, Chang CC, Zhang Q, Priya P, Zhu R, Wong ST, Landis MD, Muller WJ, Esteva FJ, Chang J, Yu D.

Cell Res. 2014 May;24(5):542-59. doi: 10.1038/cr.2014.37. Epub 2014 Mar 28.

9.

XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.

Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen Y, Mai J, Shen H, Hu DZ, Adoro S, Hu B, Song M, Tan C, Landis MD, Ferrari M, Shin SJ, Brown M, Chang JC, Liu XS, Glimcher LH.

Nature. 2014 Apr 3;508(7494):103-107. doi: 10.1038/nature13119. Epub 2014 Mar 23.

10.

Positron emitting magnetic nanoconstructs for PET/MR imaging.

Aryal S, Key J, Stigliano C, Landis MD, Lee DY, Decuzzi P.

Small. 2014 Jul 9;10(13):2688-96. doi: 10.1002/smll.201303933. Epub 2014 Mar 17.

PMID:
24639392
11.

Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts.

Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, Hong S, Adams A, D'Angelo R, Ginestier C, Charafe-Jauffret E, Clouthier SG, Birnbaum D, Wong ST, Zhan M, Chang JC, Wicha MS.

Stem Cell Reports. 2013 Dec 27;2(1):78-91. doi: 10.1016/j.stemcr.2013.11.009. eCollection 2014 Jan 14.

12.

Modeling of nanotherapeutics delivery based on tumor perfusion.

van de Ven AL, Abdollahi B, Martinez CJ, Burey LA, Landis MD, Chang JC, Ferrari M, Frieboes HB.

New J Phys. 2013 May 8;15:55004.

13.

Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.

Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC.

Breast Cancer Res. 2013;15(5):R77.

14.

A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.

Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT.

Cancer Res. 2013 Aug 1;73(15):4885-97. doi: 10.1158/0008-5472.CAN-12-4081. Epub 2013 Jun 4.

15.

Engineering discoidal polymeric nanoconstructs with enhanced magneto-optical properties for tumor imaging.

Key J, Aryal S, Gentile F, Ananta JS, Zhong M, Landis MD, Decuzzi P.

Biomaterials. 2013 Jul;34(21):5402-10. doi: 10.1016/j.biomaterials.2013.03.078. Epub 2013 Apr 20.

PMID:
23611451
16.

Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.

Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC.

Clin Cancer Res. 2013 Mar 15;19(6):1512-24. doi: 10.1158/1078-0432.CCR-11-3326. Epub 2013 Jan 22.

17.

Patient-derived breast tumor xenografts facilitating personalized cancer therapy.

Landis MD, Lehmann BD, Pietenpol JA, Chang JC.

Breast Cancer Res. 2013 Jan 22;15(1):201. doi: 10.1186/bcr3355. Review.

18.

Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells.

Zhang W, Kai K, Choi DS, Iwamoto T, Nguyen YH, Wong H, Landis MD, Ueno NT, Chang J, Qin L.

Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18707-12. doi: 10.1073/pnas.1209893109. Epub 2012 Oct 29.

19.

Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model.

Dave B, Landis MD, Tweardy DJ, Chang JC, Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D, Lewis MT.

PLoS One. 2012;7(8):e30207. doi: 10.1371/journal.pone.0030207. Epub 2012 Aug 6. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/753d15c8-2321-4dc5-9b84-c47bd1bd1639.

20.

A gene transcription signature of obesity in breast cancer.

Creighton CJ, Sada YH, Zhang Y, Tsimelzon A, Wong H, Dave B, Landis MD, Bear HD, Rodriguez A, Chang JC.

Breast Cancer Res Treat. 2012 Apr;132(3):993-1000. doi: 10.1007/s10549-011-1595-y. Epub 2011 Jul 13.

PMID:
21750966
21.

Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells.

Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Buchholz TA, Cristofanilli M, Reuben JM, Lewis MT, Woodward WA.

Mol Cancer. 2010 Jul 8;9:180. doi: 10.1186/1476-4598-9-180.

22.

LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.

Montañez-Wiscovich ME, Seachrist DD, Landis MD, Visvader J, Andersen B, Keri RA.

Oncogene. 2009 Oct 15;28(41):3608-18. doi: 10.1038/onc.2009.221. Epub 2009 Aug 3.

23.

Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.

Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM.

Cancer Res. 2008 Jun 15;68(12):4674-82. doi: 10.1158/0008-5472.CAN-07-6353.

24.

Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer.

Milliken EL, Lozada KL, Johnson E, Landis MD, Seachrist DD, Whitten I, Sutton AL, Abdul-Karim FW, Keri RA.

Oncogene. 2008 Mar 13;27(12):1759-66. Epub 2007 Sep 24.

25.
26.

Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.

Landis MD, Seachrist DD, Abdul-Karim FW, Keri RA.

Oncogene. 2006 Jun 1;25(23):3325-34. Epub 2006 Jan 23.

27.
28.

Ovarian hyperstimulation by LH leads to mammary gland hyperplasia and cancer predisposition in transgenic mice.

Milliken EL, Ameduri RK, Landis MD, Behrooz A, Abdul-Karim FW, Keri RA.

Endocrinology. 2002 Sep;143(9):3671-80.

PMID:
12193583
29.

Ontogenic development of brown adipose tissue in Angus and Brahman fetal calves.

Landis MD, Carstens GE, McPhail EG, Randel RD, Green KK, Slay L, Smith SB.

J Anim Sci. 2002 Mar;80(3):591-601.

PMID:
11890395

Supplemental Content

Loading ...
Support Center